Last reviewed · How we verify
BNT162b4 10 mcg (bnt162b4-10-mcg)
BNT162b4 10 mcg (generic name: bnt162b4-10-mcg) is a Unknown RNA therapeutics drug developed by Pfizer. It is currently FDA-approved for COVID-19 prevention.
Pfizer's BNT162b4 10 mcg is a marketed COVID-19 prevention drug. It is developed by Pfizer Inc. The mechanism of action is not specified. BNT162b4 10 mcg is primarily used for COVID-19 prevention. It has significant commercial value with revenue of 63.6B. There are no pipeline developments mentioned. The drug's clinical differentiation is not provided.
At a glance
| Generic name | bnt162b4-10-mcg |
|---|---|
| Sponsor | Pfizer |
| Drug class | Unknown |
| Target | Unknown |
| Modality | RNA therapeutics |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- COVID-19 prevention
Common side effects
Drug interactions
- Warfarin
- Aspirin
- Pain medications
- Anticoagulants
- Antiplatelets
- Corticosteroids
- Immunosuppressants
- Live vaccines
- Interferons
- Thalidomide
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BNT162b4 10 mcg CI brief — competitive landscape report
- BNT162b4 10 mcg updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about BNT162b4 10 mcg
What is BNT162b4 10 mcg?
What is BNT162b4 10 mcg used for?
Who makes BNT162b4 10 mcg?
What is the generic name of BNT162b4 10 mcg?
What drug class is BNT162b4 10 mcg in?
What development phase is BNT162b4 10 mcg in?
What does BNT162b4 10 mcg target?
Related
- Drug class: All Unknown drugs
- Target: All drugs targeting Unknown
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for COVID-19 prevention
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing